The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for InfuTronix sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
InfuTronix is a novel medical device company delivering technology for infusion therapy. It offers a new generation of infusion devices and specializes in EMS, PCEA, acute regional pain, and PCA home infusion markets. The company’s products include Nimbus Flex for low-volume infusions like chemotherapy and advanced therapeutic options; Nimbus PainPRO for a portable, and recyclable electronic pain pump in anesthetic perineural space; and Nimbus Plus for enhancing the capabilities of the device’s compact size and weight in the market size. It has partnered with Zyno Solutions LLC and Infutronix Solutions LLC. InfuTronix is headquartered in Natick, Massachusetts, the US.
The key metrics of InfuTronix related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As InfuTronix is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as InfuTronix.
For a detailed understanding of the performance of InfuTronix, buy the report here.